Skip to main
BBNX

BBNX Stock Forecast & Price Target

BBNX Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 22%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Beta Bionics is poised for significant growth as their product, the iLet Bionic Pancreas, has been well received in the market and their innovative solutions have the potential to greatly improve the lives of insulin-requiring people with diabetes. With a strong focus on expanding their product offerings and a solid financial outlook, the company is set to continue its trend of beating expectations and raising guidance. Despite some recent challenges, Beta Bionics is well positioned for success and is a top pick in the rapidly growing MedTech industry.

Bears say

Beta Bionics is a small cap med tech company that has faced significant pressure in its stock performance due to a softer SMID med tech environment. While the business is developing ahead of schedule and receiving positive attention on things like increased pharmacy new starts, a recent WL adds an element of uncertainty and distraction. With a current 2.9x forward EV/Sales multiple, we believe a discount is warranted given the company's faster revenue growth prospects, but expect the multiple to potentially re-expand to at least 4.5x, resulting in our $25 PT based on our '27E EV/Sales forecast.

BBNX has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 22% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beta Bionics Inc (BBNX) Forecast

Analysts have given BBNX a Buy based on their latest research and market trends.

According to 9 analysts, BBNX has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beta Bionics Inc (BBNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.